Download PDF
Horm Metab Res 2007; 39(2): 149-156
DOI: 10.1055/s-2007-961815
Original

© Georg Thieme Verlag KG Stuttgart · New York

Inhibition of the Androgen Receptor by Antisense Oligonucleotides Regulates the Biological Activity of Androgens in SZ95 Sebocytes

S. Fimmel 1 , A. Saborowski 1 , B. Térouanne 2 , C. Sultan 2 , C. C. Zouboulis 1 , 3
  • 1Laboratory of Biogerontology, Dermato-Pharmacology and Dermato-Endocrinology, Institute of Clinical Pharmacology and Toxicology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, Germany
  • 2INSERM U-540 (Endocrinologie Moléculaire et Cellulaire des Cancers) et Endocrinologie Pédiatrique, Hôpital A. de Villeneuve, Université Montpellier I, Montpellier, France
  • 3Departments of Dermatology and Immunology, Dessau Medical Center, Dessau, Germany
Further Information

Publication History

received 25. 11. 2005

accepted 24. 5. 2006

Publication Date:
27 February 2007 (online)

Also available at
    Permissions and Reprints

Abstract

One novel strategy for the blockade of the androgen receptor could be the selective inhibition of androgen receptor by antisense oligonucleotides or small interfering RNA molecules. Here we describe the down regulation of the androgen receptor in cultured human SZ95 sebocytes with antisense oligonucleotides modified with phosphorothioates and 2′-O-methylribosyl residues. The ability of antisense oligonucleotides to cross the cellular membrane was enhanced by establishing a transient transfection system based on cationic lipid vesicles. Both antisense oligonucleotide types administered caused assumedly translational arrest. Dose-dependent inhibition of androgen receptor protein expression was observed after SZ95 sebocyte transfection with modified phosphorothioate oligonucleotides and modified 2′-O-methylribonucleotides which were directed against the translational start of the androgen receptor mRNA. The strongest transient inhibition of androgen receptor expression was detected after 14 hours with 1.0 μM antisense 2′-O-methylribonucleotides (88±1.3%, p<0.001). With longer recovery times than 24 hours, androgen receptor protein expression returned to the native control levels. Inhibition of the expression of androgen receptor by antisense oligonucleotides, reduced the enhanced proliferation of SZ95 sebocytes challenged by testosterone and 5α-dihydrotestosterone. This administration opens new therapeutic possibilities in androgen-associated skin diseases, since we could also show androgen inhibition with these antisense oligonucleotides in a reconstituted human epidermis model (Horm Metab Res 2007; 39:157-165).

Keywords

androgens - sebaceous glands - transient transfection - biological activity

References

  • 1 Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H, Chen JD. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT.  J Biol Chem. 2003;  278 5052-5061
    CrossrefPubMedGoogle Scholar
  • 2 Verrijdt G, Haelens A, Claessens F. Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression.  Mol Genet Metab. 2003;  78 175-185
    CrossrefPubMedGoogle Scholar
  • 3 Zouboulis CC. Human skin: an independent peripheral endocrine organ.  Horm Res. 2000;  54 230-242
    CrossrefPubMedGoogle Scholar
  • 4 Hirawat S, Budman DR, Kreis W. The androgen receptor: structure, mutations, and antiandrogens.  Cancer Invest. 2003;  21 400-417
    CrossrefPubMedGoogle Scholar
  • 5 Lee DK, Chang C. Endocrine mechanisms of disease: expression and degradation of androgen receptor: mechanism and clinical implication.  J Clin Endocrinol Metab. 2003;  88 4043-4054
    CrossrefPubMedGoogle Scholar
  • 6 Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A. Androgen receptors in prostate cancer.  J Urol. 2003;  170 1363-1369
    CrossrefPubMedGoogle Scholar
  • 7 Khalkhali-Ellis Z, Handa RJ, Price Jr RH, Adams BD, Callaghan JJ, Hendrix MJ. Androgen receptors in human synoviocytes and androgen regulation of interleukin 1beta (IL-1beta) induced IL-6 production: a link between hypoandrogenicity and rheumatoid arthritis?.  J Rheumatol. 2002;  29 1843-1846
    PubMedGoogle Scholar
  • 8 Ibanez L, Ong KK, Mongan N, Jaaskelainen J, Marcos MV, Hughes IA, De Zegher F, Dunger DB. Androgen receptor gene CAG repeats polymorphism in the development of ovarian hyperandrogenism.  J Clin Endocrinol Metab. 2003;  88 3333-3338
    CrossrefPubMedGoogle Scholar
  • 9 Sasaki M, Sakuragi N, Dahiya R. The CAG repeats in exon 1 of the androgen receptor gene are significantly longer in endometrial cancer patients.  Biochem Biophys Res Commun. 2003;  305 1105-1108
    CrossrefPubMedGoogle Scholar
  • 10 Chen W, Thiboutot D, Zouboulis ChC. Cutaneous androgen metabolism: basic research and clinical perspectives.  J Invest Dermatol. 2002;  119 992-1007
    CrossrefPubMedGoogle Scholar
  • 11 Elias P, Feingold K. Coordinate regulation of epidermal differentiation and barrier homeostasis.  Skin Pharmacol Appl Skin Physiol. 2001;  14 28-34
    PubMedGoogle Scholar
  • 12 Kao JS, Garg A, Mao-Qiang M, Crumrine D, Ghadially R, Feingold KR, Elias PM. Testosterone perturbs epidermal permeability barrier homeostasis.  J Invest Dermatol. 2001;  116 443-451
    CrossrefPubMedGoogle Scholar
  • 13 Ashcroft G, Mills S. Androgen receptor-mediated inhibition of cutaneous wound healing.  J Clin Invest. 2002;  110 615-624
    CrossrefPubMedGoogle Scholar
  • 14 Zouboulis ChC, Degitz K. Androgen action on human skin - from basic research to clinical significance.  Exp Dermatol. 2004;  4 5-10
    PubMedGoogle Scholar
  • 15 Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, De La Taille A, Ackermann R, Burchardt M. The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signalling.  Int J Oncol. 2003;  23 10095-10102
    PubMedGoogle Scholar
  • 16 Hoffmann J, Sommer A. Steroid hormone receptors as targets for the therapy of breast and prostate cancer-recent advances, mechanisms of resistance and new approaches.  J Steroid Biochem Mol Biol. 2005;  93 191-200
    CrossrefPubMedGoogle Scholar
  • 17 Chi KN, Gleave ME. Antisense approaches in prostate cancer.  Expert Opin Biol Ther. 2004;  6 927-936
    PubMedGoogle Scholar
  • 18 Hamy F, Brondani V, Spoerri R, Rigo S, Stamm C, Klimkait T. Specific block of androgen receptor activity by antisense oligonucleotides.  Prostate Cancer Prostatic Disc. 2003;  6 27-33
    PubMedGoogle Scholar
  • 19 Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.  J Steroid Biochem Mol Biol. 2005;  96 251-258
    CrossrefPubMedGoogle Scholar
  • 20 Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, Bubley GJ, Balk SP. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.  J Urol. 2004;  172 1140-1144
    CrossrefPubMedGoogle Scholar
  • 21 Fimmel S, Kurfurst R, Bonté F, Zouboulis CC. Responsiveness to androgens and effectiveness of antisense oligonucleotides against the androgen receptor on human epidermal keratinocytes is dependent on the age of the donor and the location of cell origin.  Horm Metab Res. 2007;  39 157-165
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Zouboulis ChC, Seltmann H, Neitzel H, Orfanos CE. Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95).  J Invest Dermatol. 1999;  113 1011-1020
    CrossrefPubMedGoogle Scholar
  • 23 Boudon C, Lobaccaro JM, Lumbroso S, Ogur G, Ocal G, Belon C, Sultan C. A new deletion of the 5alpha-reductase type 2 gene in a Turkish family with 5 alpha-reductase deficiency.  Clin Endocrinol. 1995;  43 183-188
    CrossrefPubMedGoogle Scholar
  • 24 Fimmel S, Saborowski A, Orfanos CE, Zouboulis ChC. Development of efficient transient transfection systems for introducing antisense oligonucleotides into human epithelial skin cells.  Horm Res. 2000;  54 306-311
    CrossrefPubMedGoogle Scholar
  • 25 Oshima A, Kyle JW, Miller RD, Hoffmann JW, Powell PP, Grubb JH, Sly WS, Tropak M, Guise KS, Gravel RA. Cloning, sequencing, and expression of cDNA for human beta- glucuronidase.  Proc Natl Acad Sci USA. 1987;  84 685-689
    CrossrefPubMedGoogle Scholar
  • 26 Wróbel A, Seltmann H, Fimmel S, Müller-Decker K, Tsukada M, Bogdanoff B, Mandt N, Blume-Peytavi U, Orfanos CE, Zouboulis ChC. Differentiation and apoptosis in human immortalized sebocytes.  J Invest Dermatol. 2003;  120 175-181
    CrossrefPubMedGoogle Scholar
  • 27 Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures.  Anal Biochem. 1986;  159 109-113
    CrossrefPubMedGoogle Scholar
  • 28 Nirde P, Georget V, Terouanne B, Galifer RB, Belon C, Sultan C. Quantitation of androgen receptor messenger RNA from genital skin fibroblasts by reverse transcription-competitive polymerase chain reaction.  J Steroid Biochem Mol Biol. 1998;  66 35-43
    CrossrefPubMedGoogle Scholar
  • 29 Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones.  J Biol Chem. 1992;  267 968-974
    PubMedGoogle Scholar
  • 30 Kimura K, Markowski M, Bowen C, Gelmann EP. Androgen blocks apoptosis of hormone- dependent prostate cancer cells.  Cancer Res. 2001;  61 5611-5618
    PubMedGoogle Scholar
  • 31 Gad YZ, Berkovitz GD, Migeon CJ, Brown TR. Studies of up-regulation of androgen receptors in genital skin fibroblasts.  Mol Cell Endocrinol. 1988;  57 205-213
    CrossrefPubMedGoogle Scholar
  • 32 Chen W, Yang CC, Sheu HM, Seltmann H, Zouboulis ChC. Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes.  J Invest Dermatol. 2003;  121 441-447
    CrossrefPubMedGoogle Scholar
  • 33 Marcusson EG, Bhat B, Manoharan M, Bennett CF, Dean NM. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.  Nucleic Acid Res. 1998;  26 2016-2023
    PubMedGoogle Scholar
  • 34 Wang L, Prakash RK, Stein CA, Koehn RK, Ruffne DE. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.  Antisense Nucleic Acid Drug Dev. 2003;  13 169-189
    CrossrefPubMedGoogle Scholar
  • 35 Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H, Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism in vivo.  Proc Natl Acad Sci USA. 1996;  93 15481-15484
    CrossrefPubMedGoogle Scholar
  • 36 Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides.  Clin Pharmacokinet. 1995;  28 7-16
    PubMedGoogle Scholar
  • 37 Crooke ST, Lemonidis KM, Neilson L, Griffey R, Lesnik EA, Monia BP. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide- RNA duplexes.  Biochem J. 1995;  312 599-608
    PubMedGoogle Scholar
  • 38 Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisense oligonucleotides stabilized by locked nucleic acids.  Nucleic Acids Res. 2002;  30 1911-1918
    CrossrefPubMedGoogle Scholar
  • 39 Baker BF, Lot SS, Condon TP, Cheng S, Flournoy F, Lesnik EA, Sasmor H, Bennett CF. 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells.  J Biol Chem. 1997;  272 1994-2000
    PubMedGoogle Scholar
  • 40 Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB, Sasmor H, Manoharan M, Levin AA. Pharmacokinetic properties of 2′-O-(2-methoxy-ethyl)-modified oligonucleotide analogs in rats.  J Pharmacol Exp Ther. 2001;  296 890-897
    PubMedGoogle Scholar
  • 41 Schmitz JC, Yu D, Agrawal S, Chu E. Effect of 2′-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells.  Nucleic Acids Res. 2001;  29 415-422
    CrossrefPubMedGoogle Scholar
  • 42 Spiller DG, Giles RV, Broughton CM, Grzybowski J, Ruddell CJ, Tidd DM, Clark RE. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog- mediated biologic responses.  Antisense Nucleic Acid Drug Dev. 1998;  8 281-293
    PubMedGoogle Scholar
  • 43 Ranganathan G, Song W, Dean N, Monia B, Barger SW, Kern PA. Regulation of lipoprotein lipase by protein kinase C alpha in 3T3-F442A adipocytes.  J Biol Chem. 2002;  277 38669-38675
    CrossrefPubMedGoogle Scholar
  • 44 Reid J, Betney R, Watt K, McEwan IJ. The androgen receptor transactivation domain: the interplay between protein conformation and protein-protein interactions.  Biochem Soc Trans. 2003;  31 1042-1046
    PubMedGoogle Scholar
  • 45 Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone.  Endocrinology. 1990;  126 1165-1172
    PubMedGoogle Scholar
  • 46 Fritsch M, Orfanos CE, Zouboulis ChC. Sebocytes are the key regulators of androgen homeostasis in human skin.  J Invest Dermatol. 2001;  116 793-800
    CrossrefPubMedGoogle Scholar
  • 47 Rosenfield RL, Deplewski D, Kentsis A, Ciletti N. Mechanism of androgen induction of sebocyte differentiation.  Dermatology. 1998;  196 43-46
    CrossrefPubMedGoogle Scholar
  • 48 Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD. Androgens induce divergent proliferative responses in human breast cancer cell lines.  J Steroid Biochem Mol Biol. 1995;  52 459-467
    CrossrefPubMedGoogle Scholar
  • 49 Song CS, Jung MH, Supakar PC, Chen S, Vellanoweth RL, Chatterjee B, Roy AK. Regulation of androgen action by receptor gene inhibition.  Ann N Y Acad Sci. 1995;  761 97-108
    CrossrefPubMedGoogle Scholar
  • 50 Yeap BB, Krueger RG, Leedman PJ. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells.  Endocrinology. 1999;  40 3282-3291
    PubMedGoogle Scholar
  • 51 Krongrad A, Wilson CM, Wilson JD, Allman DR, McPhaul MJ. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells.  Mol Cell Endocrinol. 1991;  76 79-88
    CrossrefPubMedGoogle Scholar
  • 52 Wolf DA, Herzinger T, Hermeking H, Blaschke D, Horz W. Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen.  Mol Endocrinol. 1993;  7 924-936
    CrossrefPubMedGoogle Scholar
  • 53 van Erp PE, Wingens M. Does antisense make sense in Dermatology?.  Acta Derm Venereol. 2001;  81 385-391
    CrossrefPubMedGoogle Scholar
  • 54 Verma DD, Verma S, Blume G, Fahr A. Liposomes increase skin penetration of entrapped and non-entrapped hydrophilic substances into human skin: a skin penetration and confocal laser scanning microscopy study.  Eur J Pharm Biopharm. 2003;  55 271-277
    PubMedGoogle Scholar

Correspondence

C. C.Zouboulis 

Departments of Dermatology and Immunology

Dessau Medical Center

Auenweg 38

06847 Dessau

Germany

Phone: +49/340/501 40 00

Fax: +49/340/501 40 25

Email: christos.zouboulis@klinikum-dessau.de

      >